Abeona Therapeutics (ABEO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey from Stifel Nicolaus maintained a Buy rating on the stock and has a $21.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Stephen Willey has given his Buy rating due to a combination of factors that highlight Abeona Therapeutics’ promising outlook. The FDA’s broad approval of Zevaskyn for treating wounds in RDEB patients marks a significant milestone, enhancing the company’s potential for commercial success. The higher-than-expected pricing of Zevaskyn, set at $3.1 million compared to the initial estimate of $2.25 million, suggests a strong revenue potential, which is further supported by the company’s strategic outcomes-based arrangements with payers.
Willey also notes that the company’s ability to break even with a modest patient throughput and the favorable safety and efficacy profile of Zevaskyn contribute to a positive financial trajectory. The anticipated increase in treatment volumes and the strategic expansion of manufacturing capacity are expected to drive revenue growth, with the company projected to achieve sustainable profitability by the first half of 2026. These factors collectively underpin the increased target price of $21, reinforcing the Buy rating for Abeona Therapeutics.